The public health community can circle the wagons and complain about the attacking forces outside. Alternatively, public health advocates can take a hard look in the mirror, get outside of their bubble, frankly identify failures and missteps, and determine how to regain the trust of an increasingly skeptical public. The post Public Health’s Proudest Moment…
The Novo Nordisk/Ascendis partnership’s lead program is once-monthly injectable semaglutide for type 2 diabetes and obesity. This product candidate will be developed with Ascendis Pharma technology that has already yielded two FDA-approved products with longer dosing intervals. The post Novo Nordisk Commits $285M to Ascendis to Kick Off Alliance on Longer-Acting GLP-1 Drugs appeared first…
LISTEN: “People get better care when we know who they are.” That belief is at the heart of why scientists and LGBTQ+ health advocates oppose a new rule that makes it harder to collect data on trans patients with cancer. KFF Health News correspondent Rachana Pradhan appeared on WAMU’s Health Hub on Dec. 10 about…
KFF Health News chief Washington correspondent Julie Rovner discussed funding cuts at the Department of Health and Human Services on CBS News’ “24/7” on May 7. Click here to watch Rovner on “24/7.” Listen to this week’s episode of “What the Health?” — hosted by Rovner: “Cutting Medicaid Is Hard — Even for the GOP.”…
HELENA, Mont. — As Republican legislative leaders in Montana girded for this year’s battle over whether to extend Medicaid expansion in the state, they took aim at one of the program’s biggest backers: hospitals. If Montana’s hospitals wanted to extend the government health insurance program that cost taxpayers about $1 billion in 2024, and benefit…
Kaiser Permanente Ventures, Texas Medical Center Venture Fund, Yale New Haven Health join General Catalyst in $10.5 million funding round
Roche’s astegolimab met the main goal of one pivotal COPD study but failed another, mirroring the mixed results recently posted by a Regeneron Pharmaceuticals COPD drug candidate that goes after the same target. Biologics are a new treatment option for COPD following approvals of antibodies from Sanofi and GSK. The post Roche Reports Mixed Data…
By KIM BELLARD We are living, you’d have to say, in the age of bullshit. Our politicians can’t answer the simplest of questions without spouting word salad answers aimed at running out the clock until the next question. Our corporations spew endless platitudes about their lofty goals in an attempt to distract us from their…
Check out news from Oral Genome, Beacon Biosignals, Modulight Therapeutics, No Barrier, and Lab Central. The post StartUPDATES: New Developments for Healthcare Startups appeared first on MedCity News.
Hims & Hers is now offering discounted access to Wegovy, a GLP-1 manufactured by Novo Nordisk, on its platform. The post Novo Nordisk Forms GLP-1 Partnership with Hims & Hers appeared first on MedCity News.